Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

MicroRNA profile in HBV-induced infection and hepatocellular carcinoma

Authors: Guanyu Wang, Fulu Dong, Zhiyao Xu, Sherven Sharma, Xiaotong Hu, Dafang Chen, Lumin Zhang, Jinping Zhang, Qinghua Dong

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

MicroRNAs (miRNAs) exhibit essential regulatory functions related to cell growth, apoptosis, development and differentiation. Dysregulated expression of miRNAs is associated with a wide variety of human diseases. As such miRNA signatures are valuable as biomarkers for disease and for making treatment decisions. Hepatitis B virus (HBV) is a major risk factor for hepatocellular carcinoma (HCC). Here we screened for miRNAs in chronic HBV associated HCC.

Methods

To determine the miRNAs in HCC occurrence associated with HBV infection, we analyzed global miRNA expression profiles in 12 pairs of HCC and adjacent matched non-HCC tissues from HBV-positive and HBV-negative patients using microarray analyses. The microarray result was validated by real-time PCR in 32 HBV-positive and 24 HBV-negative patient HCC samples. The potential candidate target genes of the miRNAs were predicted by miRWalk software. Genes simultaneously predicted as targets by two or more miRNAs were subjected to GO and KEGG pathway analysis. The miRNA regulatory network analysis was performed using the Ingenuity Pathway Analysis (IPA) software.

Results

Eight miRNAs (miR-223, miR-98, miR-15b, miR-199a-5p, miR-19b, miR-22, miR-451, and miR-101) were involved in HBV-unrelated HCC, 5 miRNAs (miR-98, miR-375, miR-335, miR-199a-5p, and miR-22) were involved in HBV infection, and 7 miRNAs (miR-150, miR-342-3p, miR-663, miR-20b, miR-92a-3p, miR-376c-3p and miR-92b) were specifically altered in HBV-related HCC. Gene Ontology and KEGG analyses predict that these HBV-related HCC miRNAs are involved in the regulation of: transcription, RNA polymerase II promoter, phosphorylation of proteins through MAPK signaling pathway, focal adhesion, and actin cytoskeleton. IPA analysis also suggest that these miRNAs act on AGO2, TP53, CCND1, and 11 other genes that significantly influence HCC occurrence and HBV infection.

Conclusion

Our data indicates that the unique 7 miRNAs expression signature could be involved in the development HBV- related HCC.
Appendix
Available only for authorised users
Literature
1.
2.
Motavaf M, Safari S, Saffari Jourshari M, Alavian SM. Hepatitis B virus-induced hepatocellular carcinoma: the role of the virus x protein. Acta Virol. 2013;57(4):389–96.CrossRefPubMed
3.
Su IJ, Wang HC, Wu HC, Huang WY. Ground glass hepatocytes contain pre-S mutants and represent preneoplastic lesions in chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2008;23(8 Pt 1):1169–74.CrossRefPubMed
4.
Soussan P, Garreau F, Zylberberg H, Ferray C, Brechot C, Kremsdorf D. In vivo expression of a new hepatitis B virus protein encoded by a spliced RNA. J Clin Invest. 2000;105(1):55–60.CrossRefPubMedPubMedCentral
5.
El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology. 2001;33(1):62–5.CrossRefPubMed
6.
Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene. 2006;25(17):2537–45.CrossRefPubMed
7.
Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843–54.CrossRefPubMed
8.
Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell. 1993;75(5):855–62.CrossRefPubMed
9.
10.
11.
Bartel DP, Chen CZ. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet. 2004;5(5):396–400.CrossRefPubMed
12.
13.
Negrini M, Gramantieri L, Sabbioni S, Croce CM. microRNA involvement in hepatocellular carcinoma. Anti Cancer Agents Med Chem. 2011;11(6):500–21.CrossRef
14.
Hsu S, Wang B, Kota J, Yu J, Costinean S, Kutay H, et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest. 2012;122(8):2871–83.CrossRefPubMedPubMedCentral
15.
Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL, et al. MiR-199a-3p regulates mTOR and c-met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2010;70:5184–93.CrossRefPubMed
16.
Callegari E, Elamin BK, Sabbioni S, Gramantieri L, Negrini M. Role of microRNAs in hepatocellular carcinoma: a clinical perspective. Onco Targets Ther. 2013;6:1167–78.PubMedPubMedCentral
17.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25(4):402–8.CrossRefPubMed
18.
Dong F, Zhang Y, Xia F, Yang Y, Xiong S, Jin L, Zhang J. Genome-wide miRNA profiling of villus and decidua of recurrent spontaneous abortion patients. Reproduction. 2014;148(1):33–41.CrossRefPubMed
19.
de Hoon MJ, Imoto S, Nolan J, Miyano S. Open source clustering software. Bioinformatics. 2004;20(9):1453–4.CrossRefPubMed
20.
21.
Hwang GY, Lin CY, Huang LM, Wang YH, Wang JC, Hsu CT, et al. Detection of the hepatitis B virus X protein (HBx) antigen and anti-HBx antibodies in cases of human hepatocellular carcinoma. J Clin Microbiol. 2003;41(12):5598–603.CrossRefPubMedPubMedCentral
22.
Qadri I, Conaway JW, Conaway RC, Schaack J, Siddiqui A. Hepatitis B virus transactivator protein, HBx, associates with the components of TFIIH and stimulates the DNA helicase activity of TFIIH. Proc Natl Acad Sci U S A. 1996;93(20):10578–83.CrossRefPubMedPubMedCentral
23.
Elmore LW, Hancock AR, Chang SF, Wang XW, Chang S, Callahan CP, et al. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci U S A. 1997;94(26):14707–12.CrossRefPubMedPubMedCentral
24.
Liu K, Lei XZ, Zhao LS, Tang H, Liu L, Feng P, et al. Tissue microarray for high-throughput analysis of gene expression profiles in hepatocellular carcinoma. World J Gastroenterol. 2005;11(9):1369–72.CrossRefPubMedPubMedCentral
25.
Hayes CN, Akamatsu S, Tsuge M, Miki D, Akiyama R, Abe H, et al. Hepatitis B virus-specific miRNAs and Argonaute2 play a role in the viral life cycle. PLoS One. 2012;7(10):e47490.CrossRefPubMedPubMedCentral
26.
Liu WH, Yeh SH, Chen PJ. Role of microRNAs in hepatitis B virus replication and pathogenesis. Biochim Biophys Acta. 2011;1809(11–12):678–85.CrossRefPubMed
27.
Pan J, Duan LX, Sun BS, Feitelson MA. Hepatitis B virus X protein protects against anti-Fas-mediated apoptosis in human liver cells by inducing NF-kappa B. J Gen Virol. 2001;82(Pt 1):171–82.CrossRefPubMed
28.
Yen CJ, Lin YJ, Yen CS, Tsai HW, Tsai TF, Chang KY, et al. Hepatitis B virus X protein upregulates mTOR signaling through IKKβ to increase cell proliferation and VEGF production in hepatocellular carcinoma. PLoS One. 2012;7(7):e41931.CrossRefPubMedPubMedCentral
29.
Yamazaki K, Masugi Y, Sakamoto M. Molecular pathogenesis of hepatocellular carcinoma: altering transforming growth factor-β signaling in hepatocarcinogenesis. Dig Dis. 2011;29(3):284–8.CrossRefPubMed
30.
Cheong JH, Yi M, Lin Y, Murakami S. Human RPB5, a subunit shared by eukaryotic nuclear RNA polymerases, binds human hepatitis B virus X protein and may play a role in X transactivation. EMBO J. 1995;14(1):143–50.PubMedPubMedCentral
31.
Hung CH, Chiu YC, Chen CH, Hu TH. MicroRNAs in hepatocellular carcinoma: carcinogenesis, progression, and therapeutic target. Biomed Res Int. 2014;2014:486407.PubMedPubMedCentral
32.
Jiang W, Huang H, Ding L, Zhu P, Saiyin H, Ji G, et al. Regulation of cell cycle of hepatocellular carcinoma by NF90 through modulation of cyclin E1 mRNA stability. Oncogene. 2015;34(34):4460–70.CrossRefPubMed
33.
Park TJ, Chun JY, Bae JS, Park BL, Cheong HS, Lee HS, et al. CCND2 polymorphisms associated with clearance of HBV infection. J Hum Genet. 2010;55(7):416–20.CrossRefPubMed
34.
Kelso TW, Baumgart K, Eickhoff J, Albert T, Antrecht C, Lemcke S, et al. Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells. Mol Cell Biol. 2014;34(19):3675–88.CrossRefPubMedPubMedCentral
35.
36.
Amaddeo G, Cao Q, Ladeiro Y, Imbeaud S, Nault JC, Jaoui D, et al. Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas. Gut. 2015;64(5):820–9.CrossRefPubMed
37.
Wu ZJ, Zhu Y, Huang DR, Wang ZQ. Constructing the HBV-human protein interaction network to understand the relationship between HBV and hepatocellular carcinoma. J Exp Clin Cancer Res. 2010;29:146.CrossRefPubMedPubMedCentral
38.
Csepregi A, Ebert MP, Röcken C, Schneider-Stock R, Hoffmann J, Schulz HU, et al. Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma. BMC Cancer. 2010;10:317.CrossRefPubMedPubMedCentral
39.
Berzsenyi MD, Roberts SK, Beard MR. Genomics of hepatitis B and C infections: diagnostic and therapeutic applications of microarray profiling. Antivir Ther. 2006;11(5):541–52.PubMed
40.
Liu N, Zhang J, Jiao T, Li Z, Peng J, Cui Z, et al. Hepatitis B virus inhibits apoptosis of hepatoma cells by sponging the MicroRNA 15a/16 cluster. J Virol. 2013;87(24):13370–8.CrossRefPubMedPubMedCentral
41.
Li C, Wang YK, Wang CY, DU L, Zhang XH, Dong GF. Correlation of hepatitis B virus X antigen expression with liver cell apoptosis. Zhonghua Gan Zang Bing Za Zhi. 2013;21(4):252–6.PubMed
42.
Knoll S, Fürst K, Thomas S, Villanueva Baselga S, Stoll A, Schaefer S, et al. Dissection of cell context-dependent interactions between HBx and p53 family members in regulation of apoptosis: a role for HBV-induced HCC. Cell Cycle. 2011;10(20):3554–65.CrossRefPubMed
43.
Morales LD, Casillas Pavón EA, Shin JW, Garcia A, Capetillo M, Kim DJ, et al. Protein tyrosine phosphatases PTP-1B, SHP-2, and PTEN facilitate Rb/E2F-associated apoptotic signaling. PLoS One. 2014;9(5):e97104.CrossRefPubMedPubMedCentral
44.
Rotgers E, Rivero-Müller A, Nurmio M, Parvinen M, Guillou F, Huhtaniemi I, et al. Retinoblastoma protein (RB) interacts with E2F3 to control terminal differentiation of Sertoli cells. Cell Death Dis. 2014;5:e1274.CrossRefPubMedPubMedCentral
45.
Scarfò L, Ghia P. Reprogramming cell death: BCL2 family inhibition in hematological malignancies. Immunol Lett. 2013;155(1–2):36–9.CrossRefPubMed
46.
Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, van Noort M, et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet. 2003;33(3):416–21.CrossRefPubMed
47.
Yuan K, Lian Z, Sun B, Clayton MM, Ng IO, Feitelson MA. Role of miR-148a in hepatitis B associated hepatocellular carcinoma. PLoS One. 2012;7(4):e35331.CrossRefPubMedPubMedCentral
48.
Chen GG, Lai PB, Chan PK, Chak EC, Yip JH, Ho RL, et al. Decreased expression of bid in human hepatocellular carcinoma is related to hepatitis B virus X protein. Eur J Cancer. 2001;37(13):1695–702.CrossRefPubMed
49.
Lee CF, Ling ZQ, Zhao T, Lee KR. Distinct expression patterns in hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma. World J Gastroenterol. 2008;14(39):6072–7.CrossRefPubMedPubMedCentral
50.
Hung JH, Teng YN, Wang LH, Su IJ, Wang CC, Huang W, et al. Induction of Bcl-2 expression by hepatitis B virus pre-S2 mutant large surface protein resistance to 5-fluorouracil treatment in Huh-7 cells. PLoS One. 2011;6(12):e28977.CrossRefPubMedPubMedCentral
51.
Wang L, Huang J, Jiang M, Sun L. Survivin (BIRC5) cell cycle computational network in human no-tumor hepatitis/cirrhosis and hepatocellular carcinoma transformation. J Cell Biochem. 2011;112(5):1286–94.CrossRefPubMed
52.
Zhang X, Dong N, Yin L, Cai N, Ma H, You J, et al. Hepatitis B virus X protein upregulates survivin expression in hepatoma tissues. J Med Virol. 2005;77(3):374–81.CrossRefPubMed
53.
Ali M, Idrees M, Ali L, Hussain A, Ur Rehman I, Saleem S, et al. Hepatitis B virus in Pakistan: a systematic review of prevalence, risk factors, awareness status and genotypes. Virol J. 2011;8:102.CrossRefPubMedPubMedCentral
Metadata
Title
MicroRNA profile in HBV-induced infection and hepatocellular carcinoma
Authors
Guanyu Wang
Fulu Dong
Zhiyao Xu
Sherven Sharma
Xiaotong Hu
Dafang Chen
Lumin Zhang
Jinping Zhang
Qinghua Dong
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3816-1

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue

Research article

Frequency of Human papillomavirus in women attending cervical cancer screening program in Chile

Study protocol

Partnering around cancer clinical trials (PACCT): study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials

Research article

Protein kinase C inhibitor Gö6976 but not Gö6983 induces the reversion of E- to N-cadherin switch and metastatic phenotype in melanoma: identification of the role of protein kinase D1

Research article

Interval breast cancer characteristics before, during and after the transition from screen-film to full-field digital screening mammography

Research article

Galectin 3 expression in primary oral squamous cell carcinomas

Case report

Renal failure during chemotherapy: renal biopsy for assessing subacute nephrotoxicity of pemetrexed
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits